Histologic Analysis of the Lymphatic Vessels Used for Supermicrosurgical Lymphatico-venous Anastomoses in Lymphedema (s-LVA)

March 7, 2018 updated by: Paolo Gennaro

Histologic Analysis of the Lymphatic Collecting Vessels Used for Minimally Invasive Supermicrosurgical Lymphatico-venous Anastomoses in the Treatment of Lymphedema

Lymphedema, primary or secondary, is a chronic disease that causes functional impairment and has an important impact on patient's quality of life. Lymphedema can be primary or secondary. Secondary lymphedema, which is more common, especially in industrialized countries, is often due to surgery and radiotherapy to treat cancer. There is no definite cure for lymphedema; conservative treatments such as elastic compression garments, bandages and manual lymphatic drainage help reducing the edema but do not resolve it. Many types of surgery have been used in the past, the most recent are lymphatic-venous anastomoses, a minimally invasive procedure that may be performed under local anesthesia. Briefly, after visualizing the lymphatic vessels with a fluorescent dye, one or more anastomosis are created between collecting lymphatic vessels and superficial veins in order to drain the lymph into the blood stream bypassing the obstacle. During this procedure, it is possible to take samples of the collecting lymphatic vessels that are to be anastomosed with veins and use them for histological and immunohistochemical studies, without causing any additional discomfort to the patient. These samples can be formalin fixed and paraffin embedded. The obtained sections will be stained with a lymphatic endothelium marker and a smooth muscle specific stain. A morphometric study will be conducted and, based on the results a statistical evaluation will be made. The analysis will be conducted on samples obtained from patients, affected by secondary or primary lymphedema willing to provide their free and informed consent. The aim of this study is to evaluate the histopathological characteristics of the collecting lymphatic vessels that have been anastomosed with adjacent veins during surgery, and relate the results with the obtained clinical response. The acquired knowledge will contribute to optimize the clinical approach to prevent and treat lymphedema, by helping to select the patients that will benefit more from the surgery, and to select vessels and anatomical sites that have better chances to provide efficient anastomoses.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Background:

Lymphedema is a chronic pathologic condition that causes significant functional impairment to the patient and has a great impact on his quality of life. It may be primary or secondary. Secondary lymphedema, that is the most common, is generally due to surgery and radiotherapy for cancer, particularly of the breast, uterus and prostate but can also occur after a trauma. Primary lymphedema can be congenital or begin at puberty, or more rarely after age 35, in this case, often following a trigger event such as trauma or infection.

There is no specific treatment for this highly disabling disease and patients must lifelong try to reduce edema and limit its progression by the use of elastic compression garments and with manual lymphatic drainage. Over the years several surgical approaches have been proposed, including more recently super microsurgical lymphatic-venous anastomosis (sLVA) to allow drainage of the lymph in the venous stream distal to the obstruction. sLVA is a minimally invasive procedure performed under local anesthesia with discharge the day after surgery. It requires an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. In selected cases, magnetic resonance can also be useful. Small samples of the vessel selected to perform the LVA can easily be taken during surgery, formalin-fixed and paraffin-embedded for histologic and immunohistochemical studies without further discomfort or complications for the patient.

Knowledge on the histopathological aspects of lymphedema is extremely limited, this study must therefore be considered an exploratory one, possibly intended to generate more hypotheses than to solve them. A better understanding of the physio-pathological mechanisms of lymphedema can lead to a more effective surgical approach and, in selected cases, even prevent its development with considerable advantages in terms of the patient's quality of life and also in reducing national health care system costs (direct costs arising from the need to undergo continuous physiotherapy and indirect costs due to disability, serious intercurrent infections requiring hospitalization and loss of work days).

Primary purpose of the study is to evaluate the histopathologic features of the lymphatic vessels anastomosed with veins. The primary purpose will be divided in two phases: 1. on secondary lymphedema; 2. on primary lymphedema.

Secondary purpose of the study is the correlation of histopathologic parameters with other clinical data: type of lymphedema (primary versus secondary), age of the patient, years from the onset of the disease, anatomic site of the anastomosis, morphologic characteristics of the vessel as assessed pre-operatively by lymphography and or magnetic resonance imaging.

The acquired knowledge will be valuable to customize the approach to prevent and treat lymphedema. In particular, will help to:

  1. Select patients who can better benefit from sLVA and within them prioritize intervention.
  2. Select the lymphatic vessels that are more likely to give an efficient anastomosis with veins.
  3. Based on the comparison between the morphological features of lymphatic vessels of various parts of the limb affected by lymphedema, select the anatomical sites where efficient anastomosis are more likely to be achieved.

Experimental design This is a single center, non commercial laboratory study to be performed on human biological material. Patients will be recruited with a consecutive participant sampling of all those who meet the eligibility criteria and are willing to provide informed consent. Samples of the lymphatic vessels to be anastomosed with veins will be taken at time of sLVA, this can be done without any inconvenience for the patient because the lymphatic vessels are often too long and a segment must be removed to perform the anastomosis. Usually during surgery 1-3 lymphatic vessels/patient are removed for technical reasons. These samples instead of being destroyed, will be transported to the laboratory of Prof. Elisabetta Weber where they will be formalin-fixed and paraffin embedded. Histologic and immunohistochemical studies will be performed on the obtained sections stained with appropriate markers and or/stains for the lymphatic endothelium (D2-40 and VEGFR-3) and of smooth muscle cells. Appropriate stains will be used to determine the relative proportions of smooth muscle cells and collagen fibers in the lymphatic wall. A morphometric analysis of data will be performed and data will be related with the clinical results obtained.

All data will be statistically evaluated. As there are no previous experiences that allow to estimate the variability of the parameters in the study, it is not possible to hazard a formal analysis of the statistical power of the study. However, a sample of 25 patients should be sufficient to provide a first estimate of the variability of the parameters and inform future efficacy studies based on the hypothesis testing model tests (Tukey, 1977). Since the sample comprises two different types of lymphedema, primary and secondary, a minimum of 25 patients is required to have a sufficient number of patients for each of these two groups. It will not be difficult to find cases of secondary lymphedema, since it is very common (especially in industrialized countries, as a consequence of surgery and radiotherapy for cancer treatment), while it will be more difficult to find cases of primary lymphedema since this type of lymphedema is rare and often undiagnosed or misdiagnosed. Should the individual variability be considerable, it would be necessary to increase the number of patients. Finally, it should be noted that, given the small size of the samples (maximum of 0.4mm diameter, 2-5mm in length), not all histological preparations will be successful. Therefore, the investigators believe it prudent to set a maximum number of samples of 200.

The statistical analysis will make use, as well as of descriptive methods, of methods of comparison and correlation of parametric (Student t, linear correlation) or non-parametric (logistics analysis, chi-square, Spearman's rank correlation), in agreement to the features of the data distribution that will be found. The correlation between the time from onset of lymphedema and primary and secondary outcomes will be investigated with Cox proportional hazard model. Differences in outcome measures between recent (<1 year) and long standing lymphedema will be investigated using Generalized Linear Models using gaussian family and identity link. When more than one sample from the same patient is present, the patient will be included in the model as a random effect variable. A p value of 0.05 or less for a two tails distribution will be considered statistically significant. Data is presented as M ± robust SE All the analyses will be performed using Stata vers. 12 (Stata Corp, College Station, TX).

Aim of the study:

The aim is to better understand the pathogenetic aspects and pathophysiology of lymphedema (of which very little is known) and evaluate the structure of lymphatic vessel in relation to the stage of lymphedema, to optimize the choice of the lymphatic vessels better suited to achieve functioning anastomoses. The obtained data will be correlated with clinical outcome which will be evaluated with the following objective parameters: reduction in limb circumference measured at several points (hand, wrist, -5 cm from the elbow, elbow and +5 cm from the elbow; for leg: foot, ankle, -10 cm from the knee, the knee, to +10 cm from the knee); reduction/absence of episodes of lymphangitis; decreasing compression class of elastic compression garments. Subjective parameters will also be evaluated as indexes of the patient's life quality: reduction of discomfort, reduced sense of heaviness, ability to wear clothes more easily, improved social life.

The study will be conducted in accordance with the ethical principles in the Declaration of Helsinki in its latest revision. Participation in the study will be subject to obtaining the free and informed consent.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Siena, Italy, 53100
        • Recruiting
        • Dept. of Maxillofacial Surgery, Azienda Ospedaliera Universitaria Senese
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Virginia Barone, PhD
        • Sub-Investigator:
          • Annalisa Borghini, PhD
        • Sub-Investigator:
          • Guido Gabriele, MD
        • Sub-Investigator:
          • Erica Tedone Clemente, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All the patients affected by lymphedema that come to us to undergo s-LVA surgery, that match the eligibility criteria and give their free and informed consent. There is no restriction of sex, gender, race, ethnics, country, region, town, etc.

Description

Inclusion Criteria:

  • age over 18 years old;
  • patients affected by primary or secondary lymphedema;
  • patients willing to give their free and informed consent.

Exclusion Criteria:

  • patients currently undergoing radiotherapy;
  • patients currently undergoing chemotherapy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with lymphedema
Patients affected by primary or secondary lymphedema. The intervention will consist in supermicrosurgical lymphatico-venous anastomoses (sLVA) to allow drainage of the lymph in the venous stream distal to the obstruction. sLVA is a minimally invasive procedure performed under local anesthesia. It requires an accurate visualization of the lymphatic vessels that are still functional.
Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Expression of the lymphatic endothelial marker D2-40 in relation with the duration of lymphedema.
Time Frame: Collection of samples from different sites of at least 10 patients will require at least 6 months
On sections stained with D2-40, under light microscopy with the aid of the morphometric program NIS elements tracing the portions of the endothelium stained positively for this marker and comparing the sum of all positive segments of each vessel with the length of its inner profile. The duration of lymphedema in number of years can be obtained using previous medical records (e.g. lymphography or lymphoscintigraphy) when the patient comes to observation after the diagnosis has already been made or, when no previous medical record is available, through the anamnesis. The duration of lymphedema from clinical onset to the time of surgery is expressed in number of years.
Collection of samples from different sites of at least 10 patients will require at least 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Area of the vessel wall versus area of the lumen
Time Frame: Collection of samples from different sites of at least 10 patients will require at least 6 months
Subtracting the inner from the outer profile with the aid of the morphometric program NIS elements.
Collection of samples from different sites of at least 10 patients will require at least 6 months
The relative proportion of smooth muscle cells and collagen fibers in the lymphatic vessel wall.
Time Frame: Collection of samples from different sites of at least 10 patients will require at least 6 months
Staining with Trichrome stain and measuring the threshold of the stained area (threshold of red for smooth muscle cells, threshold of blue for collagen fibers).
Collection of samples from different sites of at least 10 patients will require at least 6 months
Differences in the histology of lymphatics between primary and secondary lymphedema.
Time Frame: Since primary lymphedema is rare, collection of an adequate number of cases of primary lymphedema (at least 10) to evaluate whether there are histologic differences with secondary lymphedema will require at least three years.
Histologic measurements are the same as for the primary outcome. To determine if the lymphedema is primary or secondary an accurate anamnesis is usually enough: patients report history of trauma or cancer treatment in case of secondary lymphedema, no such events in primary lymphedema.
Since primary lymphedema is rare, collection of an adequate number of cases of primary lymphedema (at least 10) to evaluate whether there are histologic differences with secondary lymphedema will require at least three years.
Relation between the anatomic site of the anastomosis and histologic parameters.
Time Frame: Collection of samples from different sites of at least 10 patients will require at least 6 months.
Measurement of histologic parameters as in the primary outcome, comparison between samples taken from different sites of the same patient (hand or wrist versus elbow, or more rarely arm, for the upper limb, foot or ankle versus knee or more rarely thigh, for the lower limb).
Collection of samples from different sites of at least 10 patients will require at least 6 months.
Correlation between histologic modifications and morphologic appearance at lymphography and / or at MRL (Magnetic Resonance Lymphography).
Time Frame: Collection of samples from different sites of at least 10 patients will require at least 6 months
Lymphography with a fluorescent dye (indocyanine green), routinely performed prior to surgery to choose the lymphatic vessels suitable for anastomoses. In later stage lymphedemas, MRL, with gadolinium as a contrast medium, is sometimes necessary to allow visualization of lymphatic vessels thanks to the slow wash out of gadolinium. Histologic evaluation as in the primary outcome.
Collection of samples from different sites of at least 10 patients will require at least 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: Paolo Gennaro, MD, PhD, Department of Biotechnology, University of Siena; Department of Maxillofacial Surgery, Azienda Ospedaliera Universitaria Senese
  • Principal Investigator: Elisabetta Weber, MD, University of Siena, Dept. of Molecular and Developmental Medicine.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2017

Primary Completion (Anticipated)

December 31, 2018

Study Completion (Anticipated)

December 31, 2023

Study Registration Dates

First Submitted

December 7, 2017

First Submitted That Met QC Criteria

March 7, 2018

First Posted (Actual)

March 15, 2018

Study Record Updates

Last Update Posted (Actual)

March 15, 2018

Last Update Submitted That Met QC Criteria

March 7, 2018

Last Verified

March 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

For technical reasons we do not yet know which type of data may be obtained and hence cannot make plans for data sharing.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphedema

3
Subscribe